“Phase 3 Trial Demonstrates Superior Patient Treatment Convenience of MC2-01 Calcipotriene Plus Betamethasone Dipropionate Cream Compared to Current Topical Suspension”, J of Skin, vol. 4, no. 5, p. s62, Sep. 2020, doi: 10.25251/skin.4.supp.61.